Keynote Speaker: David Bartel (Whitehead Institute for Biomedical Research, Howard Hughes Medical Institute, MIT)Presented by the Biochemical Pharmacology Discussion Group
Reported by Jennifer Cable | Posted December 12, 2016
MicroRNAs (miRNAs) are short, noncoding RNA molecules that repress the translation of target mRNAs. Because of their roles in many important cellular processes, miRNAs are attractive candidates as drug targets, or as drugs themselves. Several miRNA therapies have recently made their way into clinical trials for cancer and hepatitis C virus (HCV) infection, while preclinical research is underway in a variety of other diseases.
On July 13, 2016, clinicians and basic researchers from academia and industry convened at the New York Academy of Sciences for the MicroRNAs: A Gene Silencing Mechanism with Therapeutic Implications symposium. Presenters discussed preclinical and clinical data for miRNA-based therapy as well as new insights in the basic functions of miRNAs. The meeting was presented by the Biochemical Pharmacology Discussion Group and the New York Academy of Sciences.
Use the tabs above to find a meeting report and multimedia from this event.
Presentations available from:
David Bartel (Whitehead Institute for Biomedical Research, Howard Hughes Medical Institute, MIT)
Frank Slack (Beth Israel Deaconess Medical Center, Harvard Medical School)
Joana Vidigal (Memorial Sloan Kettering Cancer Center)
M. Mahmood Hussain (SUNY Downstate Medical Center)
Hin Hark Gan (New York University)
David S. Hong (The University of Texas MD Anderson Cancer Center)
The Biochemical Pharmacology Discussion Group is proudly supported by:
How to cite this eBriefing
The New York Academy of Sciences. MicroRNAs: A Gene Silencing Mechanism with Therapeutic Implications. Academy eBriefings. 2016. Available at: www.nyas.org/miRNA-eB